BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hassan AM, Osman HA, Mahmoud HS, Hassan MH, Hashim AA, Ameen HH. Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist 2018;11:895-901. [PMID: 29983581 DOI: 10.2147/IDR.S167093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Danishwar M, Jamil Z, Khan S, Nakhla M, Ahmad I, Ali MA, Lau DTY. Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. JCM 2022;11:984. [DOI: 10.3390/jcm11040984] [Reference Citation Analysis]
3 Arruda RM, Batista AD, Filgueira NA, Moura IF, Sette LH, Lopes EP. Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy. J Bras Nefrol 2021;43:117-20. [PMID: 33022028 DOI: 10.1590/2175-8239-JBN-2019-0165] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]